AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
12 May 2014 06:15 PM
RNS
Form 8 (OPD) AstraZeneca PLC
12 May 2014 04:01 PM
RNS
AZ ANNOUNCES RESULTS OF PHASE IIB STUDIES
12 May 2014 04:00 PM
RNS
AZ TO PRESENT DATA AT ATS 2014
12 May 2014 03:25 PM
BZW
Form 8.3 - AstraZeneca Plc
12 May 2014 03:09 PM
BZW
Form 8.3 - Astrazenica Plc
12 May 2014 01:58 PM
BZW
Form 8.3 - AstraZeneca PLC
12 May 2014 12:12 PM
BZW
Form 8.3 - Astrazeneca Plc
12 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
12 May 2014 07:00 AM
RNS
AMGEN & AZ BRODALUMAB PHASE III RESULTS
09 May 2014 02:15 PM
BZW
Form 8.3 - Astrazeneca Plc
09 May 2014 02:06 PM
BZW
Form 8.3 - AstraZeneca Plc
09 May 2014 01:54 PM
BZW
Form 8.3 - AstraZeneca PLC
09 May 2014 11:43 AM
BZW
Form 8.3 - Astrazeneca Plc
09 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
08 May 2014 04:23 PM
BZW
Form 8.3 - AstraZeneca Plc
08 May 2014 02:08 PM
BZW
Form 8.3 - Astrazeneca Plc
08 May 2014 12:54 PM
BZW
Form 8.3 - AstraZeneca PLC
08 May 2014 12:31 PM
RNS
ASTRAZENECA INITIATES PHASE III STUDY FOR MEDI4736
08 May 2014 11:32 AM
BZW
Form 8.3 - Astrazeneca Plc
08 May 2014 11:02 AM
RNS
Rule 2.10 Announcement
07 May 2014 05:30 PM
RNS
Holding(s) in Company
07 May 2014 04:56 PM
BZW
Form 8.3 - Astrazeneca Plc
07 May 2014 03:27 PM
BZW
Form 8.3 - AstraZeneca Plc
07 May 2014 01:41 PM
BZW
Form 8.3 - AstraZeneca PLC
07 May 2014 01:39 PM
BZW
Form 8.3 - Astrazenica Plc
07 May 2014 11:18 AM
BZW
Form 8.3 - Astrazeneca Plc
07 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
06 May 2014 04:02 PM
BZW
Form 8.3 - ASTRAZENECA PLC
06 May 2014 03:30 PM
RNS
Changes to membership of Board Committees
06 May 2014 03:12 PM
BZW
Form 8.3 - AstraZeneca Plc
06 May 2014 01:12 PM
BZW
Form 8.3 - AstraZeneca PLC
06 May 2014 01:10 PM
BZW
Form 8.3 - AstraZeneca PLC
06 May 2014 12:31 PM
BZW
Form 8.3 - Astrazeneca Plc
06 May 2014 11:30 AM
RNS
Rule 2.10 Announcement
06 May 2014 11:00 AM
RNS
ASTRAZENECA ISSUES UPDATE ON STRATEGY
06 May 2014 07:01 AM
RNS
US FDA APPROVES EPANOVA
06 May 2014 07:00 AM
BZW
Form 8.3 - Astrazeneca - Amendment
06 May 2014 07:00 AM
BZW
Form 8.3 - AstraZeneca Plc
02 May 2014 04:07 PM
BZW
Form 8.3 - AstraZeneca
02 May 2014 03:06 PM
BZW
Form 8.3 - AstraZeneca Plc
02 May 2014 02:24 PM
BZW
Form 8.3 - Astrazeneca Plc
02 May 2014 01:41 PM
BZW
Form 8.3 - AstraZeneca PLC
02 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
02 May 2014 10:50 AM
RNS
ASTRAZENECA BOARD REJECTS PFIZER PROPOSAL
02 May 2014 08:09 AM
RNS
STATEMENT REGARDING PFIZER ANNOUNCEMENT
01 May 2014 04:47 PM
BZW
Form 8.3- ASTRAZENECA PLC
01 May 2014 03:28 PM
BZW
Form 8.3 - AstraZeneca Plc
01 May 2014 01:37 PM
BZW
Form 8.3 - AstraZeneca plc
01 May 2014 01:15 PM
BZW
Form 8.3 - AstraZeneca PLC
01 May 2014 11:00 AM
RNS
Rule 2.10 Announcement

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings